News | April 30, 2013

Zilver PTX Drug Eluting Stent Recalled Due to Catheter Separation Issue

Cook Medical received 13 complaints of delivery system tip separation


April 30, 2013 — Cook Medical has initiated a global voluntary recall of its Zilver PTX Drug Eluting Peripheral Stent based on its investigation into a small number of complaints that the delivery system of the device had separated at the tip of the inner catheter. Cook received 13 complaints of delivery system tip separation with an occurrence rate of 0.043 percent. Two adverse events, including one death, occurred in cases where a tip separation was reported.

Potential adverse events that may occur in cases where inner delivery catheter breakage occurs include: possible surgery to remove the catheter tip, vascular occlusion due to an unretrieved catheter tip, thrombosis, amputation and possible cardiac arrest.

These devices were distributed to medical institutions in the United States between Dec. 13, 2012 and April 16, 2013. Cook initiated a voluntary global recall of all sizes, diameters and lot numbers. Consignees should stop using the device, quarantine any inventory and return it for credit.

The recall, said Rob Lyles, vice president and global leader of Cook Medical’s Peripheral Interventional clinical division, is specific to the delivery system, not the stent itself. If a patient has had a Zilver PTX stent implanted and the delivery system was removed safely and intact, that patient is at no risk and is not affected by this recall. Bare metal versions of Cook Medical’s Zilver Flex stent use a different delivery system that is not included in this recall.

Cook’s investigation identified an internal component of the delivery system used to implant the stent that did not consistently meet established design criteria. Cook has conducted an exhaustive quality assessment and audit of the affected components to ensure satisfactory performance of the delivery system in the future.

For more information: www.cookmedical.com


Related Content

News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Subscribe Now